Clinical Trials Logo

Clinical Trial Summary

Malignant ascites and pleural effusion are common symptoms in patients with advanced cancer. Currently, the management of malignant ascites and pleural effusion is a considerable clinical challenge. The investigator hypothesized that tumor cell-derived microparticles packaging chemotherapeutic drugs might be a useful means to treat malignant ascites and pleural effusion. Thirty malignant ascites or pleural effusion patients will be recruited for Phase II clinical trials.


Clinical Trial Description

Ascites or pleural effusion were first removed from patients. The patients were then locally injected with microparticles packaging chemotherapeutic drugs 4 times a week. The therapeutic effects and side effects were recorded. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01854866
Study type Interventional
Source Huazhong University of Science and Technology
Contact
Status Enrolling by invitation
Phase Phase 2
Start date May 2013
Completion date March 2014

See also
  Status Clinical Trial Phase
Recruiting NCT06200376 - A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer Phase 1
Completed NCT04051112 - Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites Phase 1
Completed NCT00836654 - Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Phase 2/Phase 3
Not yet recruiting NCT05501340 - PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Phase 1/Phase 2
Not yet recruiting NCT03550560 - EUS-Guided Drainage of Refractory Malignant Ascites
Recruiting NCT04501744 - A Study of M701 (EpCAM and CD3) in Malignant Ascites Phase 1
Terminated NCT00028782 - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer N/A
Recruiting NCT05477927 - Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases Phase 1
Active, not recruiting NCT06266091 - Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody Phase 2
Withdrawn NCT04076566 - Malignant Ascites Alfapump® Study
Recruiting NCT03230708 - Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites Phase 1/Phase 2
Completed NCT01327235 - Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Phase 2
Recruiting NCT06432296 - Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody Phase 3
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Terminated NCT02496286 - Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Phase 1
Completed NCT01532427 - ALFApump System Post Marketing Surveillance Registry
Completed NCT00326885 - Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Phase 2
Recruiting NCT02530398 - A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites Phase 1
Withdrawn NCT00908219 - A Study of Bevacizumab to Prevent Malignant Ascites Phase 2
Recruiting NCT06016179 - Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Phase 1